1F0R

CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR208815

Summary for 1F0R

• Entry DOI: 10.2210/pdb1f0r/pdb
• Related: 1EZQ 1F0S 1F0T 1F0U
• Descriptor: COAGULATION FACTOR XA, CALCIUM ION, THIENO[3,2-B]PYRIDINE-2-SULFONIC ACID [1-(1-AMINO-ISOQUINOLIN-7-YLMETHYL)-2-OXO-PYRROLDIN-3-YL]-AMIDE, ... (5 entities in total)
• Functional Keywords: protein-inhibitor complex, hydrolase
• Biological source: Homo sapiens (human); More
• Cellular location: Secreted: P00742 P00742
• Total number of polymer chains: 2
• Total formula weight: 44255.00

Authors

Maignan, S.,Guilloteau, J.P.,Pouzieux, S.,Choi-Sledeski, Y.M.,Becker, M.R.,Klein, S.I.,Ewing, W.R.,Pauls, H.W.,Spada, A.P.,Mikol, V. (deposition date: 2000-05-17, release date: 2000-09-20, Last modification date: 2024-03-13)

Primary citation

Maignan, S.,Guilloteau, J.P.,Pouzieux, S.,Choi-Sledeski, Y.M.,Becker, M.R.,Klein, S.I.,Ewing, W.R.,Pauls, H.W.,Spada, A.P.,Mikol, V.
Crystal structures of human factor Xa complexed with potent inhibitors.
J.Med.Chem., 43:3226-3232, 2000

PubMed Abstract: Involved in the coagulation cascade, factor Xa (FXa) is a serine protease which has received great interest as a potential target for the development of new antithrombotics. Although there is a great wealth of structural data on thrombin complexes, few structures of ligand/FXa complexes have been reported, presumably because of the difficulty in growing crystals. Reproducible crystallization conditions for human des-Gla1-45 coagulation FXa have been found. This has led to an improvement in the diffraction quality of the crystals (about 2.1 A) when compared to the previously reported forms (2.3-2.8 A) thus providing a suitable platform for a structure-based drug design approach. A series of crystal structures of noncovalent inhibitors complexed with FXa have been determined, three of which are presented herein. These include compounds containing the benzamidine moiety and surrogates of the basic group. The benzamidine-containing compound binds in a canonical fashion typical of synthetic serine protease inhibitors. On the contrary, molecules that contain surrogates of the benzamidine group do not make direct hydrogen-bonding interactions with the carboxylate of Asp189 at the bottom of the S1 pocket. The structural data provide a likely explanation for the specificity of these inhibitors and a great aid in the design of bioavailable potent FXa inhibitors.

PubMed: 10966741
DOI: 10.1021/jm000940u

Experimental method

X-RAY DIFFRACTION (2.1 Å)